Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism
Introduction: Hepatocellular carcinoma (HCC) has been associated to non-alcoholic fatty liver disease (NAFLD). We sought to investigate the immunoexpression of several glycolytic metabolism-associated markers in patients with HCC associated to NAFLD and associate these factors to their clinical-path...
Gespeichert in:
Veröffentlicht in: | Pathobiology (Basel) 2022, Vol.89 (3), p.157-165 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 165 |
---|---|
container_issue | 3 |
container_start_page | 157 |
container_title | Pathobiology (Basel) |
container_volume | 89 |
creator | Granja, Sara Costa Longatto-Filho, Adhemar de Campos, Priscila B. Oliveira, Claudia P. Stefano, José T. Martins-Filho, Sebastião N. Chagas, Aline L. Herman, Paulo D’Albuquerque, Luiz C. Reis Alvares-da-Silva, Mário Carrilho, Flair José Baltazar, Fátima Alves, Venâncio A.F. |
description | Introduction: Hepatocellular carcinoma (HCC) has been associated to non-alcoholic fatty liver disease (NAFLD). We sought to investigate the immunoexpression of several glycolytic metabolism-associated markers in patients with HCC associated to NAFLD and associate these factors to their clinical-pathological characteristics. Methods: We evaluated 35 HCC specimens from 21 patients diagnosed with non-alcoholic steatohepatitis (NASH) undergoing liver resection (12 patients), liver transplantation (8 patients), or both (1 patient). Histological features, clinical aspects, demographic and biochemical data, as well as the immunohistochemical reactivity for monocarboxylate transporters 1, 2, and 4; their chaperone CD147; carbonic anhydrase IX; and glucose transporter-1 (GLUT1) were assessed. Results: Metabolic-associated cirrhosis was present in 12 of the 21 patients (8 child A and 4 child B scores). From 9 patients without cirrhosis, 3 presented NASH F3 and 6 NASH F2. Sixteen (76%) had diabetes mellitus, 17 (81%) arterial hypertension, and 19 (90%) body mass index above 25 kg/m 2 ; 8 (38%) had dyslipidemia. From 35 nodules, steatosis was found in 26, ballooning in 31 nodules, 25 of them diagnosed as steatohepatitic subtype of HCC. MCT4 immunoexpression was associated with extensive intratumoral fibrosis, advanced clinical stages, and shorter overall survival. GLUT1 was noticeable in nodules with extensive intratumoral steatosis, higher intratumoral fibrosis, and advanced clinical stages. Immunohistochemical expression of the metabolic biomarkers MCT4 and GLUT1 was higher in patients with Barcelona-clinic liver cancer B or C. GLUT1 correlated with higher degree of steatosis, marked ballooning, intratumoral fibrosis, and higher parenchymal necroinflammatory activity. Conclusion: Our data indicate that the expression of the glycolytic phenotype of metabolic markers, especially GLUT1 and MCT4, correlates with a more severe course of HCC occurring in NASH patients. |
doi_str_mv | 10.1159/000521034 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000521034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2621253249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-12fbfea786ecfee38e3aa669085cfcfbbf08544d732c9c1c3bdb99fa68a199d33</originalsourceid><addsrcrecordid>eNptkE1v1DAQhq0K1C964I6QJS7tIeCPJI25rUK_pC0g1J6jiTNmQ-N48SRI_QX87Xq1y544zSvNo2c0L2NvpfgoZWE-CSEKJYXOD9ixzJXOhDLyVcpCFpkSojpiJ0S_ElaJUhyyI12IXCmpj9nfr2HMFoMNqzD0ll_DND3zZf8HI__SEwJh9gMHmLDjt7iGKVgchnmAyGuIth-Dh8_8zvt5DKue0nqFvrcw8AUREnkcJx4cv4f4hJE2sYbRJnudPPweJ2jTYfJv2GsHA-HZbp6yx-urh_o2W367uasXy8xqnU-ZVK51CJdVidYh6go1QFkaURXWWde2LqU87y61ssZKq9uuNcZBWYE0ptP6lJ1vvesYfs9IU-N72vwEI4aZGlUqqQqtcpPQiy1qYyCK6Jp17D3E50aKZtN7s-89se932rn12O3Jf0Un4MMWeIL4E-Me-L542CqadecS9e6_1O7KC9CclJo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2621253249</pqid></control><display><type>article</type><title>Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism</title><source>Karger Journals</source><creator>Granja, Sara Costa ; Longatto-Filho, Adhemar ; de Campos, Priscila B. ; Oliveira, Claudia P. ; Stefano, José T. ; Martins-Filho, Sebastião N. ; Chagas, Aline L. ; Herman, Paulo ; D’Albuquerque, Luiz C. ; Reis Alvares-da-Silva, Mário ; Carrilho, Flair José ; Baltazar, Fátima ; Alves, Venâncio A.F.</creator><creatorcontrib>Granja, Sara Costa ; Longatto-Filho, Adhemar ; de Campos, Priscila B. ; Oliveira, Claudia P. ; Stefano, José T. ; Martins-Filho, Sebastião N. ; Chagas, Aline L. ; Herman, Paulo ; D’Albuquerque, Luiz C. ; Reis Alvares-da-Silva, Mário ; Carrilho, Flair José ; Baltazar, Fátima ; Alves, Venâncio A.F.</creatorcontrib><description>Introduction: Hepatocellular carcinoma (HCC) has been associated to non-alcoholic fatty liver disease (NAFLD). We sought to investigate the immunoexpression of several glycolytic metabolism-associated markers in patients with HCC associated to NAFLD and associate these factors to their clinical-pathological characteristics. Methods: We evaluated 35 HCC specimens from 21 patients diagnosed with non-alcoholic steatohepatitis (NASH) undergoing liver resection (12 patients), liver transplantation (8 patients), or both (1 patient). Histological features, clinical aspects, demographic and biochemical data, as well as the immunohistochemical reactivity for monocarboxylate transporters 1, 2, and 4; their chaperone CD147; carbonic anhydrase IX; and glucose transporter-1 (GLUT1) were assessed. Results: Metabolic-associated cirrhosis was present in 12 of the 21 patients (8 child A and 4 child B scores). From 9 patients without cirrhosis, 3 presented NASH F3 and 6 NASH F2. Sixteen (76%) had diabetes mellitus, 17 (81%) arterial hypertension, and 19 (90%) body mass index above 25 kg/m 2 ; 8 (38%) had dyslipidemia. From 35 nodules, steatosis was found in 26, ballooning in 31 nodules, 25 of them diagnosed as steatohepatitic subtype of HCC. MCT4 immunoexpression was associated with extensive intratumoral fibrosis, advanced clinical stages, and shorter overall survival. GLUT1 was noticeable in nodules with extensive intratumoral steatosis, higher intratumoral fibrosis, and advanced clinical stages. Immunohistochemical expression of the metabolic biomarkers MCT4 and GLUT1 was higher in patients with Barcelona-clinic liver cancer B or C. GLUT1 correlated with higher degree of steatosis, marked ballooning, intratumoral fibrosis, and higher parenchymal necroinflammatory activity. Conclusion: Our data indicate that the expression of the glycolytic phenotype of metabolic markers, especially GLUT1 and MCT4, correlates with a more severe course of HCC occurring in NASH patients.</description><identifier>ISSN: 1015-2008</identifier><identifier>EISSN: 1423-0291</identifier><identifier>DOI: 10.1159/000521034</identifier><identifier>PMID: 35042213</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Research Article</subject><ispartof>Pathobiology (Basel), 2022, Vol.89 (3), p.157-165</ispartof><rights>2022 S. Karger AG, Basel</rights><rights>2022 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-12fbfea786ecfee38e3aa669085cfcfbbf08544d732c9c1c3bdb99fa68a199d33</citedby><cites>FETCH-LOGICAL-c334t-12fbfea786ecfee38e3aa669085cfcfbbf08544d732c9c1c3bdb99fa68a199d33</cites><orcidid>0000-0001-5285-4460 ; 0000-0002-5779-9752 ; 0000-0002-7404-2540</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,2431,4026,27930,27931,27932</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35042213$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Granja, Sara Costa</creatorcontrib><creatorcontrib>Longatto-Filho, Adhemar</creatorcontrib><creatorcontrib>de Campos, Priscila B.</creatorcontrib><creatorcontrib>Oliveira, Claudia P.</creatorcontrib><creatorcontrib>Stefano, José T.</creatorcontrib><creatorcontrib>Martins-Filho, Sebastião N.</creatorcontrib><creatorcontrib>Chagas, Aline L.</creatorcontrib><creatorcontrib>Herman, Paulo</creatorcontrib><creatorcontrib>D’Albuquerque, Luiz C.</creatorcontrib><creatorcontrib>Reis Alvares-da-Silva, Mário</creatorcontrib><creatorcontrib>Carrilho, Flair José</creatorcontrib><creatorcontrib>Baltazar, Fátima</creatorcontrib><creatorcontrib>Alves, Venâncio A.F.</creatorcontrib><title>Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism</title><title>Pathobiology (Basel)</title><addtitle>Pathobiology</addtitle><description>Introduction: Hepatocellular carcinoma (HCC) has been associated to non-alcoholic fatty liver disease (NAFLD). We sought to investigate the immunoexpression of several glycolytic metabolism-associated markers in patients with HCC associated to NAFLD and associate these factors to their clinical-pathological characteristics. Methods: We evaluated 35 HCC specimens from 21 patients diagnosed with non-alcoholic steatohepatitis (NASH) undergoing liver resection (12 patients), liver transplantation (8 patients), or both (1 patient). Histological features, clinical aspects, demographic and biochemical data, as well as the immunohistochemical reactivity for monocarboxylate transporters 1, 2, and 4; their chaperone CD147; carbonic anhydrase IX; and glucose transporter-1 (GLUT1) were assessed. Results: Metabolic-associated cirrhosis was present in 12 of the 21 patients (8 child A and 4 child B scores). From 9 patients without cirrhosis, 3 presented NASH F3 and 6 NASH F2. Sixteen (76%) had diabetes mellitus, 17 (81%) arterial hypertension, and 19 (90%) body mass index above 25 kg/m 2 ; 8 (38%) had dyslipidemia. From 35 nodules, steatosis was found in 26, ballooning in 31 nodules, 25 of them diagnosed as steatohepatitic subtype of HCC. MCT4 immunoexpression was associated with extensive intratumoral fibrosis, advanced clinical stages, and shorter overall survival. GLUT1 was noticeable in nodules with extensive intratumoral steatosis, higher intratumoral fibrosis, and advanced clinical stages. Immunohistochemical expression of the metabolic biomarkers MCT4 and GLUT1 was higher in patients with Barcelona-clinic liver cancer B or C. GLUT1 correlated with higher degree of steatosis, marked ballooning, intratumoral fibrosis, and higher parenchymal necroinflammatory activity. Conclusion: Our data indicate that the expression of the glycolytic phenotype of metabolic markers, especially GLUT1 and MCT4, correlates with a more severe course of HCC occurring in NASH patients.</description><subject>Research Article</subject><issn>1015-2008</issn><issn>1423-0291</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNptkE1v1DAQhq0K1C964I6QJS7tIeCPJI25rUK_pC0g1J6jiTNmQ-N48SRI_QX87Xq1y544zSvNo2c0L2NvpfgoZWE-CSEKJYXOD9ixzJXOhDLyVcpCFpkSojpiJ0S_ElaJUhyyI12IXCmpj9nfr2HMFoMNqzD0ll_DND3zZf8HI__SEwJh9gMHmLDjt7iGKVgchnmAyGuIth-Dh8_8zvt5DKue0nqFvrcw8AUREnkcJx4cv4f4hJE2sYbRJnudPPweJ2jTYfJv2GsHA-HZbp6yx-urh_o2W367uasXy8xqnU-ZVK51CJdVidYh6go1QFkaURXWWde2LqU87y61ssZKq9uuNcZBWYE0ptP6lJ1vvesYfs9IU-N72vwEI4aZGlUqqQqtcpPQiy1qYyCK6Jp17D3E50aKZtN7s-89se932rn12O3Jf0Un4MMWeIL4E-Me-L542CqadecS9e6_1O7KC9CclJo</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Granja, Sara Costa</creator><creator>Longatto-Filho, Adhemar</creator><creator>de Campos, Priscila B.</creator><creator>Oliveira, Claudia P.</creator><creator>Stefano, José T.</creator><creator>Martins-Filho, Sebastião N.</creator><creator>Chagas, Aline L.</creator><creator>Herman, Paulo</creator><creator>D’Albuquerque, Luiz C.</creator><creator>Reis Alvares-da-Silva, Mário</creator><creator>Carrilho, Flair José</creator><creator>Baltazar, Fátima</creator><creator>Alves, Venâncio A.F.</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5285-4460</orcidid><orcidid>https://orcid.org/0000-0002-5779-9752</orcidid><orcidid>https://orcid.org/0000-0002-7404-2540</orcidid></search><sort><creationdate>2022</creationdate><title>Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism</title><author>Granja, Sara Costa ; Longatto-Filho, Adhemar ; de Campos, Priscila B. ; Oliveira, Claudia P. ; Stefano, José T. ; Martins-Filho, Sebastião N. ; Chagas, Aline L. ; Herman, Paulo ; D’Albuquerque, Luiz C. ; Reis Alvares-da-Silva, Mário ; Carrilho, Flair José ; Baltazar, Fátima ; Alves, Venâncio A.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-12fbfea786ecfee38e3aa669085cfcfbbf08544d732c9c1c3bdb99fa68a199d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Granja, Sara Costa</creatorcontrib><creatorcontrib>Longatto-Filho, Adhemar</creatorcontrib><creatorcontrib>de Campos, Priscila B.</creatorcontrib><creatorcontrib>Oliveira, Claudia P.</creatorcontrib><creatorcontrib>Stefano, José T.</creatorcontrib><creatorcontrib>Martins-Filho, Sebastião N.</creatorcontrib><creatorcontrib>Chagas, Aline L.</creatorcontrib><creatorcontrib>Herman, Paulo</creatorcontrib><creatorcontrib>D’Albuquerque, Luiz C.</creatorcontrib><creatorcontrib>Reis Alvares-da-Silva, Mário</creatorcontrib><creatorcontrib>Carrilho, Flair José</creatorcontrib><creatorcontrib>Baltazar, Fátima</creatorcontrib><creatorcontrib>Alves, Venâncio A.F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathobiology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Granja, Sara Costa</au><au>Longatto-Filho, Adhemar</au><au>de Campos, Priscila B.</au><au>Oliveira, Claudia P.</au><au>Stefano, José T.</au><au>Martins-Filho, Sebastião N.</au><au>Chagas, Aline L.</au><au>Herman, Paulo</au><au>D’Albuquerque, Luiz C.</au><au>Reis Alvares-da-Silva, Mário</au><au>Carrilho, Flair José</au><au>Baltazar, Fátima</au><au>Alves, Venâncio A.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism</atitle><jtitle>Pathobiology (Basel)</jtitle><addtitle>Pathobiology</addtitle><date>2022</date><risdate>2022</risdate><volume>89</volume><issue>3</issue><spage>157</spage><epage>165</epage><pages>157-165</pages><issn>1015-2008</issn><eissn>1423-0291</eissn><abstract>Introduction: Hepatocellular carcinoma (HCC) has been associated to non-alcoholic fatty liver disease (NAFLD). We sought to investigate the immunoexpression of several glycolytic metabolism-associated markers in patients with HCC associated to NAFLD and associate these factors to their clinical-pathological characteristics. Methods: We evaluated 35 HCC specimens from 21 patients diagnosed with non-alcoholic steatohepatitis (NASH) undergoing liver resection (12 patients), liver transplantation (8 patients), or both (1 patient). Histological features, clinical aspects, demographic and biochemical data, as well as the immunohistochemical reactivity for monocarboxylate transporters 1, 2, and 4; their chaperone CD147; carbonic anhydrase IX; and glucose transporter-1 (GLUT1) were assessed. Results: Metabolic-associated cirrhosis was present in 12 of the 21 patients (8 child A and 4 child B scores). From 9 patients without cirrhosis, 3 presented NASH F3 and 6 NASH F2. Sixteen (76%) had diabetes mellitus, 17 (81%) arterial hypertension, and 19 (90%) body mass index above 25 kg/m 2 ; 8 (38%) had dyslipidemia. From 35 nodules, steatosis was found in 26, ballooning in 31 nodules, 25 of them diagnosed as steatohepatitic subtype of HCC. MCT4 immunoexpression was associated with extensive intratumoral fibrosis, advanced clinical stages, and shorter overall survival. GLUT1 was noticeable in nodules with extensive intratumoral steatosis, higher intratumoral fibrosis, and advanced clinical stages. Immunohistochemical expression of the metabolic biomarkers MCT4 and GLUT1 was higher in patients with Barcelona-clinic liver cancer B or C. GLUT1 correlated with higher degree of steatosis, marked ballooning, intratumoral fibrosis, and higher parenchymal necroinflammatory activity. Conclusion: Our data indicate that the expression of the glycolytic phenotype of metabolic markers, especially GLUT1 and MCT4, correlates with a more severe course of HCC occurring in NASH patients.</abstract><cop>Basel, Switzerland</cop><pmid>35042213</pmid><doi>10.1159/000521034</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5285-4460</orcidid><orcidid>https://orcid.org/0000-0002-5779-9752</orcidid><orcidid>https://orcid.org/0000-0002-7404-2540</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1015-2008 |
ispartof | Pathobiology (Basel), 2022, Vol.89 (3), p.157-165 |
issn | 1015-2008 1423-0291 |
language | eng |
recordid | cdi_crossref_primary_10_1159_000521034 |
source | Karger Journals |
subjects | Research Article |
title | Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T22%3A43%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-Alcoholic%20Fatty%20Liver%20Disease-Related%20Hepatocellular%20Carcinoma:%20Immunohistochemical%20Assessment%20of%20Markers%20of%20Cancer%20Cell%20Metabolism&rft.jtitle=Pathobiology%20(Basel)&rft.au=Granja,%20Sara%20Costa&rft.date=2022&rft.volume=89&rft.issue=3&rft.spage=157&rft.epage=165&rft.pages=157-165&rft.issn=1015-2008&rft.eissn=1423-0291&rft_id=info:doi/10.1159/000521034&rft_dat=%3Cproquest_cross%3E2621253249%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2621253249&rft_id=info:pmid/35042213&rfr_iscdi=true |